FDA Brief

Warning letters Drugs

FDA warning letter to

Nefeteri Wellness

High riskIssued May 30, 2025Posted Jun 17, 2025Office of Unapproved Drugs and Labeling Compliance

FDA says Nefeteri Wellness sells two unapproved colloidal silver vaginal gels promoted to treat infections.

What happened

On April 2, 2025, FDA reviewed the company's website labeling at thelotusfreshline.com, where "LOTUS FRESH™ intimate/flora gel" and "LOTUS FRESH™ v-gel moisturize & balance" are offered for sale in the United States without a prescription. The website describes the gels as fighting yeast and bacterial vaginosis and calls colloidal silver a "natural antibiotic" that treats infections. FDA treats these claims as evidence the products are drugs sold without an approved application.

What FDA found

  1. The website claims the gels treat infections, which makes them drugs under the law.

    Section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B)-(C)
  2. The products are new drugs because no FDA-approved application is in effect for them.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  3. Sending these products into interstate commerce is prohibited.

    Section 301(d) of the FD&C Act, 21 U.S.C. 331(d)
  4. Any over-the-counter drug with colloidal silver that claims to treat disease is automatically treated as a new drug needing approval.

    21 CFR 310.548(b)
  5. The website wording is what shows the company intends the products to be used as drugs.

    21 CFR 201.128

What FDA wants

FDA tells the company to write within 15 working days describing the specific steps taken to fix the violations and prevent them from happening again, with supporting documents. If the company thinks it is not in violation, it must send its reasoning and evidence.

Who should pay attention

  • online sellers of herbal or colloidal silver "feminine wellness" products
  • retailers and marketplaces that list items with infection-treatment claims
  • brands whose product pages are written by marketing staff rather than regulatory reviewers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk